Literature DB >> 7511020

Profiles of cytokines (TNF alpha and IL-6) and acute phase proteins (CRP and alpha 1AG) related to the disease course in patients with systemic lupus erythematosus.

C Meijer1, V Huysen, R T Smeenk, A J Swaak.   

Abstract

Tumor necrosis factor alpha (TNF alpha) and interleukin-6 (IL-6) play a main role in inducing acute phase protein production by hepatocytes. This study describes the serum levels of TNF alpha and IL-6 in relation to serum levels of C-reactive protein (CRP) and alpha 1-acid glycoprotein (alpha 1AG) in three systemic lupus erythematosus (SLE) patients. Disease courses of these patients were divided in a total of 19 clinical periods, according to the clinical symptoms and interleukin profiles. Significantly elevated TNF alpha levels were found in all but three of the defined periods, without being associated with disease activity. In only four of the defined periods elevated TNF alpha were observed combined with elevated IL-6 and CRP levels. Two of these periods coincided with minor symptoms of SLE, one with an exacerbation and the other one with a systemic infection while SLE activity was low. All other periods showed varying combinations of elevated TNF alpha and/or IL-6 levels being followed or not by elevated CRP levels. Significantly raised alpha 1AG levels were measured in all clinical periods. In most of the observed periods a dissociation was found between TNF alpha and IL-6 and also between the different cytokine (TNF alpha and IL-6) levels and acute phase protein (CRP and alpha 1AG) levels. These data could not be explained by differences in disease course or influences of medication. We conclude that more factors other than TNF alpha and IL-6 must play a role in the regulatory pathway of the acute phase response in SLE.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7511020     DOI: 10.1177/096120339300200605

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  17 in total

Review 1.  Tumour necrosis factor and other cytokines in murine lupus.

Authors:  A N Theofilopoulos; B R Lawson
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Measurement and analysis of unbound drug concentrations.

Authors:  J D Wright; F D Boudinot; M R Ujhelyi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

3.  Monocytes from systemic lupus erythematous patients are severely altered in phenotype and lineage flexibility.

Authors:  F Steinbach; F Henke; B Krause; B Thiele; G R Burmester; F Hiepe
Journal:  Ann Rheum Dis       Date:  2000-04       Impact factor: 19.103

4.  Increased expression of human T-cell immunoglobulin- and mucin-domain-containing molecule-4 in peripheral blood mononuclear cells from patients with system lupus erythematosus.

Authors:  Peiqing Zhao; Liyun Xu; Piming Wang; Xiaohong Liang; Jianni Qi; Peng Liu; Chun Guo; Lining Zhang; Chunhong Ma; Lifen Gao
Journal:  Cell Mol Immunol       Date:  2010-02-08       Impact factor: 11.530

Review 5.  The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications.

Authors:  D A Horwitz; C O Jacob
Journal:  Springer Semin Immunopathol       Date:  1994

6.  Initial validation of a novel protein biomarker panel for active pediatric lupus nephritis.

Authors:  Michiko Suzuki; Kristina Wiers; Elizabeth B Brooks; Kenneth D Greis; Kathleen Haines; Marisa S Klein-Gitelman; Judyann Olson; Karen Onel; Kathleen M O'Neil; Earl D Silverman; Lori Tucker; Jun Ying; Prasad Devarajan; Hermine I Brunner
Journal:  Pediatr Res       Date:  2009-05       Impact factor: 3.756

7.  Cytokine-induced monocyte characteristics in SLE.

Authors:  Zhe Zhang; Kelly Maurer; Juan C Perin; Li Song; Kathleen E Sullivan
Journal:  J Biomed Biotechnol       Date:  2010-06-24

8.  Circulating CD4(+) and CD8(+) T cells are activated in inflammatory bowel disease and are associated with plasma markers of inflammation.

Authors:  Nicholas T Funderburg; Samantha R Stubblefield Park; Hannah C Sung; Gareth Hardy; Brian Clagett; James Ignatz-Hoover; Clifford V Harding; Pingfu Fu; Jeffry A Katz; Michael M Lederman; Alan D Levine
Journal:  Immunology       Date:  2013-09       Impact factor: 7.397

Review 9.  Newer drugs for the treatment of lupus nephritis.

Authors:  Dudy G Kuiper-Geertsma; Ronald H W M Derksen
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  High-sensitivity C-reactive protein, disease activity, and cardiovascular risk factors in systemic lupus erythematosus.

Authors:  Chi Chiu Mok; Daniel J Birmingham; Ling Yin Ho; Lee A Hebert; Brad H Rovin
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-03       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.